Package 69367-132-06

{"route": ["ORAL"], "spl_id": "b779d072-7cc4-4fa2-9421-0e8ea96334cd", "openfda": {"nui": ["N0000008486"], "unii": ["6CW7F3G59X"], "rxcui": ["310430", "310431", "310432"], "spl_set_id": ["2f70c496-b58c-30f5-e054-00144ff8d46c"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "manufacturer_name": ["Westminster Pharmaceuticals, LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "500 CAPSULE in 1 BOTTLE (69367-132-06)", "package_ndc": "69367-132-06", "marketing_end_date": "20261201", "marketing_start_date": "20160401"}], "brand_name": "Gabapentin", "product_id": "69367-132_b779d072-7cc4-4fa2-9421-0e8ea96334cd", "dosage_form": "CAPSULE", "pharm_class": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "product_ndc": "69367-132", "generic_name": "Gabapentin", "labeler_name": "Westminster Pharmaceuticals, LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Gabapentin", "active_ingredients": [{"name": "GABAPENTIN", "strength": "300 mg/1"}], "application_number": "ANDA204989", "marketing_category": "ANDA", "marketing_end_date": "20261201", "marketing_start_date": "20160401"}